tbuckley/cabot-search huggingface dataset:
Usefulness of screening chest roentgenograms in preoperative patients
Authors: L. Rucker
Journal: JAMA (1983)

We proposed that clinical criteria could define a group of patients very unlikely to have abnormal preoperative chest roentgenograms. Nine hundred five surgical admissions were screened for the presence of clinical factors we thought would make those patients more likely to have abnormal preoperative chest roentgenograms. Of these, 368 had no risk factors. One patient (0.3%) of the 368 had an abnormal x-ray film, which did not affect the surgery. No material abnormalities were found in the remainder of the group without risk factors. Five hundred four patients had identifiable risk factors. Of these, 114 (22%) were found to have serious abnormalities on preoperative chest roentgenogram. (<i>JAMA</i>1983;250:3209-3211)
HYDRALAZINE POISONING
Authors: Edward D. Freis
Journal: JAMA (1960)

<h3>To the Editor:—</h3> The paper entitled "Hydralazine Poisoning" by Bendersky and Ramirez inThe Journal, Aug. 20, page 1789, is written as if there were no question that hydralazine produced the fatal syndrome. There is room, however, for a slight suspicion that hydralazine may not have been the etiological factor. In the first place, the patient received only 100 mg. per day, which is well below the dosage levels at which the lupus-like syndrome usually appears. In fact, as the authors point out, Dustan and associates continued to treat their patients who developed "hydralazine poisoning" on reduced dosages of 150 to 300 mg. per day with no disastrous results except recurrent mild arthralgia. In my personal experience with several hundred patients treated with hydralazine in dosages of 200 mg. or less daily for periods of one to nine years, no serious toxic reactions have appeared. The authors also point out
HEALTH OF CHICAGO.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thrombocytosis
Authors: Andrew I. Schafer
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editorial: Treatment of retinitis pigmentosa.
Journal: BMJ (1976)

the cervix with prostaglandin before vacuum aspiration may perhaps be extended to include patients for mid-trimester abortion with the aim of reducing cervical trauma.Methods for mid-trimester termination will continue to improve.Nevertheless, inevitably their efficiency depends on understanding the role of prostaglandin in stimulating uterine muscle activity and that of progesterone and 173 oestradiol in the maintenance of pregnancy.
Health Effects of Acid Aerosols on North American Children: Air Pollution Exposures
Authors: John D. Spengler, Petros Koutrakis, Douglas W. Dockery, Mark Raizenne, Frank E. Speizer
Journal: Environmental Health Perspectives (1996)

Air pollution measurements were conducted over a 1-year period in 24 North American communities participating in a respiratory health study. Ozone, particle strong acidity, sulfate, and mass (PM10 and PM2.1) were measured in all communities. In 20 of the communities, sulfur dioxide, ammonia, nitric acid, nitrous acid, and particulate nitrate were measured. The sampler was located centrally in the community whenever possible and samples were collected every other day. Concentrations of particle strong acidity, mass, sulfate, and ozone were highly correlated both in the region of the country defined as a high-sulfur source area and in the downwind transport regions. These regions of the eastern United States and southern Canada experienced the greatest particle strong acidity, sulfate, and particle mass concentrations during the spring and summer months (May-September). The particle strong acidity concentrations were highest in regions close to the high sulfur emission areas of the United States; that is, in the area immediately to the west of the Appalachian Plateau and west of the Allegheny Mountains (western Pennsylvania, eastern Ohio, and West Virginia) up through southern Ontario. The frequency of particle strong acidity events decreased with transport distance from the region of highest sulfur emissions. Low particle strong acidity and sulfates were found at the western and midwestern sites of both the United States and Canada. Substantial concentrations of nitric acid were found in two of the California sites as well as many sites in the northeastern portion of the United States. Sites selected for the epidemiologic study provide a range of annual mean particle strong acidity exposures from below the limit of detection to more than 50 nmol/m3.
International Symposium on Cancer Immunology
Journal: JNCI Journal of the National Cancer Institute (1969)

Journal Article International Symposium on Cancer Immunology Get access JNCI: Journal of the National Cancer Institute, Volume 43, Issue 1, July 1969, Pages 315–316, https://doi.org/10.1093/jnci/43.1.315-a Published: 01 July 1969
A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
Authors: Fatima Karzai, Avani Atul Shah, Michelle A. Ojemuyiwa, Ravi Amrit Madan, Andrea Borghese Apolo, Nancy Ann Dawson, Philip M. Arlen, Marc Robert Theoret, John Joseph Wright, Clara Chen, Jane B. Trepel, Anna Couvillon, Guinevere Chun, Nancy Harold, Seth M. Steinberg, Douglas K. Price, James L. Gulley, William Douglas Figg, William L. Dahut
Journal: Journal of Clinical Oncology (2014)

5072 Background: Two landmark trials demonstrate docetaxel improves overall survival in metastatic castrate-resistant prostate cancer (mCRPC). Benefits remain short-lived requiring evaluation of other treatment options, including docetaxel (D) combinations. Combining D with other agents, such as cabozantinib (C) could target different cellular signaling pathways producing either additive or synergistic activities without overlapping toxicities. C is a multikinase inhibitor of c-Met, vascular endothelial growth factor receptor 2, and RET, which has shown activity in mCRPC. Methods: Patients (pts) with no prior history of D, receive D at 75 mg/m2 IV on day 1 of a 21 day cycle, and prednisone (P) at 5 mg po q12 hours, with C at three dose levels: 20 mg, 40 mg, or 60 mg po daily. Three-six pts are treated at each dose level until the maximum tolerated dose (MTD) has been defined. Results: Fifteen pts have been accrued; 4 at 20 mg C, 6 at 40 mg C, and 5 at 60 mg C. Median age is 67 (45-84 yrs). Median baseline PSA is 69.46 (0.01-521.5 ng/mL). Median Gleason score is 9 (7-10). Four pts have ECOG PS of 0 and 11 pts have a PS of 1. Six pts have bone only disease and 8 pts have bone and soft tissue/visceral disease (STD). Median number of cycles is 9 (1-23). Most common Grade 2 and 3 adverse events (AE’s), possibly related to C are: anemia (2/14), diarrhea (2/14), hand/foot syndrome (3/14), fatigue (3/14), hypophosphatemia (4/14), and oral mucositis (4/14). Of 13 evaluable pts, PSA declines are seen in 7 pts (4 declines at 40 mg C, 3 declines at 60 mg C). Two pts with bone only disease have resolution of some lesions on bone scan (BS) and both pts had PSA declines >30%. 4 pts with bone only disease have stable BS, and of these, 2 pts had PSA declines >20%. Two pts with bone and STD have PSA declines >30% and stable imaging results. Of 15 pts, six month PFS is 83.9% (95% CI: 56.3% to 95.5%) and 9 month PFS is 59.9%. Conclusions: The addition of C to D and P has shown to have a tolerable side effect profile. An expansion cohort will be enrolled at the MTD to further characterize safety, toxicity, and to obtain additional information on the efficacy of the combination treatment. Clinical trial information: NCT01683994.
Synergy of understanding dermatologic disease and epidermal biology
Authors: John R. Stanley
Journal: Journal of Clinical Investigation (2012)

All authors agree to retract the above article due to multiple use of the same images or manipulation of data in Figures 1A,2D, 5C, 6B, 6C, and 8A and Supplemental Figure 8E.They are also not able to provide some of the raw data that are used in Figures 2A,2B, 5, 6, 7C, 8, and 9C, Supplemental Tables 1234, and Supplemental Figures 2C,3, 4, 5, 7C, 8A-8C, 8E, 8F, 10A, and 10B.The first author, Fei Wang, has admitted his sole responsibility in altering figures.The authors apologize and deeply regret the impact of this action.However, the authors stand behind data showing that genetic deletion of S1pr2 or pharmacological S1PR2 inhibition alleviates atherosclerosis in Apoe -/-mice fed a high-cholesterol diet.
MORE ADVICE TO AUTHORS
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sixth Annual Symposium on Fine Needle Aspiration
Journal: JNCI Journal of the National Cancer Institute (1986)

Sixth Annual Symposium on Fine Needle Aspiration Get access JNCI: Journal of the National Cancer Institute, Volume 76, Issue 4, April 1986, Pages 779–780, https://doi.org/10.1093/jnci/76.4.779-d Published: 01 April 1986
Abstract 3176: Biomarker identification using xenograft mouse model based clinical trial simulation and artificial intelligence data analytics
Authors: M Afshar, Francis Bichat, Olivier Duchamp, A Etcheto, Damien France, M Kindermans, Caroline Mignard, F Parmentier, Hery Ratsima
Journal: Cancer Research (2019)

Abstract The growing number of anti-cancer drugs available at different stages of clinical development combined with the broadening potential use of combination therapy further complexifies the early identification of companion markers, markers of synergy as well as novel indications for existing and new drug combinations. Well characterized patient derived xenograft mouse models (PDX), combined with Artificial Intelligence tools that can integrate and analyze the broad range of generated data can help address this challenge. PDX experiments can providing an opportunity to simulate a clinical assessment using multiple mice models.In this study, we developed a PDX platform combined with the KEM® Artificial Intelligence data analytics, that is based on Formal Concept Analysis, to simulate a clinical trial and identify biomarkers of response. The platform was tested on colon cancer patient derived PDX. Respectively mRECIST response and survival of respectively 21 and 26 PDXs against Oxalipaltin combined with 5-Fluorouracil and folinic acid (Folfox) was experimentally assessed against a placebo, simulating a clinical trial-like setting with 2 arms. Biomarkers of response (mRECIST) and survival were identified using KEM®, combined with statistical modelling (Cox survival-modelling). 24 candidate biomarker genes were identified including PGAP3, ERBB2, NOTCH2, WDR70, and ZNF227. Alone or combined, these biomarkers are significantly linked to an increase or decrease of the survival PDX (p ranging from 2.2e-10 to 0.048, odd-ratio ranging from 0.12 to 10.00), with the potential to be used as inclusion or exclusion biomarkers. This work demonstrates the ability of a combined PDX / Artificial Intelligence platform to simulate clinical trials and identify biomarkers of drug efficacy and synergy, thus fostering the design of precision medicine clinical trials. Citation Format: M Afshar, Francis Bichat, Olivier Duchamp, A Etcheto, Damien France, M Kindermans, Caroline Mignard, F Parmentier, Hery Ratsima. Biomarker identification using xenograft mouse model based clinical trial simulation and artificial intelligence data analytics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3176.
CORRESPONDENCE.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechanistic isolationism
Authors: Z. Danilevicius
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Late-breaking and Chrysalis abstracts presented at scientific sessions, AAAAI 60th Anniversary Meeting, March 7–12, 2003
Authors: J Boswell, P Savage, Q Guan, J Walsh, M Schellenberg, T Winter, E Winter, C Lil, C Debrosse, N Zimmermann, N King, S Pope, P Fulker- Son, A Mishra, M Rothenberg
Journal: Journal of Allergy and Clinical Immunology (2003)
Unravelling the molecular determinants of metabolic syndrome thanks to NMR-metabolomics of urine and serum samples
Authors: Chiara Bruzzone, Rubén Gil-Redondo, Laura delaCruz-Villar, Arantza Sanz-Parra, Dolores Corella, Nieves Embade, José M. Mato, Oscar Millet
Journal: Journal of Hepatology (2020)
Conference Report: Transatlantic contrasts: the BMA at San Diego
Journal: BMJ (1981)

Transatlantic contrasts: the BMA at San Diego I-Doctors and medicine in jeopardy Some linguistic experts insist that in another 200 years the Americans and the English will speak different languages.English, despite jumbo jets and Hollywood films, will, they say, fragment into several distinct languages just as Latin did over 1000 years ago, and an Englishman visiting the United States will need an interpreter.Undeterred by the possibility of being misunderstood, almost 1000 British doctors and their spouses took themselves to the BMA Congress in that most exotic part of the United States, California, to see how big the differences were.
Incorrect Specialty
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rapid assessment of corticotropin reserve after pituitary surgery
Authors: N. B. Watts
Journal: JAMA (1988)

Corticotropin deficiency may occur after pituitary surgery, and, if unrecognized and untreated, it can be fatal. In this study the insulin tolerance test was used to assess hypothalamic-pituitary-adrenal reserve five to seven days after pituitary surgery, and postoperative morning serum cortisol concentration was compared with the insulin tolerance test for predicting corticotropin deficiency. In 35 patients with pituitary tumors studied prospectively, 27 had normal insulin tolerance test results five to seven days after pituitary surgery; in these patients, the morning serum cortisol concentration two to three days after surgery was 250 nmol/L (9 μg/dL) or greater. Eight patients had subnormal insulin tolerance test results or clinical evidence of adrenal insufficiency; the morning serum cortisol concentration in these patients was 80 nmol/L (3 μg/dL) or less. Postoperative adrenal insufficiency was transient (one to three months) in five of these eight patients. We retrospectively identified 45 patients whose postoperative morning serum cortisol values were 200 nmol/L (7 μg/dL) or greater; none of these patients had clinical evidence of adrenal insufficiency. We conclude that a morning serum cortisol level obtained two to three days after surgery and 24 hours after the discontinuation of hydrocortisone accurately predicts postoperative corticotropin reserve. (<i>JAMA</i>1988;259:708-711)
AIDS serology testing in low- and high-risk groups
Authors: J. R. Carlson
Journal: JAMA (1985)

The performance characteristics of the acquired immunodeficiency syndrome (AIDS)—retrovirus serological tests including enzyme-linked immunosorbent assay (ELISA), Western blot, and immunofluorescence assay were defined in a clinical laboratory setting by testing 1,257 serum specimens from low- and high-risk groups for AIDS. The three prototype AIDS retroviruses (lymphadenopathy-associated virus, human T-lymphotropic virus III, and AIDS-associated retrovirus) were equally suitable as target antigen for these assays. Sera from six of 74 laboratory and health care personnel and 91 of 1,014 unselected blood donors were falsely positive by ELISA (positive to negative ratio [P/N], ≥2) based on the lack of Western blot confirmation. Only two true-positives (two [0.2%] of 1,014 blood donors) were detected in these low-risk groups. In contrast, 106 of 108 specimens with ELISA P/N ratios of 2 or greater from the high-risk groups including asymptomatic homosexual men, hemophiliacs, AIDS-related complex patients, and AIDS patients were positive by Western blot and immunofluorescence assay. Four false-negative ELISA results based on positive immunofluorescence assay and Western blot were found in the AIDS patient group. Ten of 69 AIDS patients were negative by all three serological tests. The consequence of maintaining high sensitivity for the ELISA (P/N ratio, ≥2) as a screening test was a loss of specificity. The number of false-positive results necessitated the use of a confirmation test with greater specificity. (<i>JAMA</i>1985;253:3405-3408)
Chemical Carcinogenesis
Authors: Hugues J.-P. Ryser
Journal: New England Journal of Medicine (1971)

CANCER can be induced in animals with ionizing radiations, oncogenic viruses or chemical carcinogens. Abnormal exposures to radiations increase the incidence of leukemias and skin and bone tumors in man, but the low exposure we endure in everyday life is not considered an important cause of human tumors. Epidemiologic data suggest a link between a lymphoma prevailing in East and Central Africa, the Burkitt lymphoma and an insect-transmitted virus. Evidence has been mounting recently that some human leukemias and sarcomas might be caused by an as yet unidentified virus. There is no solid basis, however, for assuming a role of . . .